

PIMSH13 Mutation Testing for Stage IV Lung Cancer Prior to Treatment

In this lesson you will learn the required documentation for the **MIPS # PIMSH13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy** quality measure.

- E/M visit in reporting period (99202-99205; 99211-99215)
- Non-squamous NSCLC lung ca diagnosis
- Metastatic DX or 2nd or more line of therapy diagnosis between July 1st of the previous performance period through June 30th of the current performance period
- Testing for all actionable biomarkers
 - NTRK1/2/3; RET; MET; ROS1; EGFR; EGFR T790M; BRAF mutation; ALK rearrangement; CD274(PD-L1); KRAS; ERBB2 mutation
- If positive biomarker results are received for the values listed, AND the correct drug is given = Numerator Met
- If positive biomarker results are received and the correct drug IS NOT given, THEN Numerator Not Met.
- Any chemotherapy within the measurement period.
- *AND* lung cancer treated with appropriate mutation-directed therapy or standard chemotherapy if biomarker results are negative

The screenshot shows the 'Clinical Profile' tab in the iKnowMed interface. The 'Problems' sub-tab is selected. In the 'New Problem' section, the 'Problem (required)' field is set to 'non-small cell lung cancer'. The 'Status' is 'Active'. Below this, there are fields for 'Date of Diagnosis', 'Comment', 'Details', and 'ICD-10'. To the right, a search bar contains 'non-small cell lung cancer'. Below the search bar, the 'Search Results' section displays two items: 'Non-small cell lung cancer' (with a 'PW' icon and a star) and 'Squamous NSCLC (non-small cell lung cancer)' (also with a 'PW' icon and a star). A red box highlights the first result, and a red circle with the number '1' points to it.

1. Add the diagnosis to the problem list.

iKnowMedSM Generation 2

Metastasis [clear](#)

☐ M0: No distant metastasis

☐ M1: Distant metastasis

M1a: Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgement dictate that the effusion is not related to a tumor, the effusion should be excluded as a staging descriptor

☐ M1b: Single extrathoracic metastasis in a single organ (including involvement of a single nonregional node)

☐ M1c: Multiple extrathoracic metastases in a single organ or in multiple organs

☐ MX: Primary tumor cannot be assessed

Other

2. Metastatic disease is documented as **Metastasis** of 1 or greater and Stage IV. *Metastatic disease may also be indicated by a numbered line of therapy or documentation of metastatic site.*

Histopathologic Type

Histologic Grade

Tumor Size (cm)

EGFR Expression

ALK

PD-L1

KRAS gene

ROS1 Gene

BRAF Mutation


MET gene mutation

RET gene mutation

3. Click the arrow to the right of each mutation to document testing results for: **EGFR Expression, ALK (FISH), PD-L1, KRAS, ROS1 Gene, BRAF Mutation.**

iKnowMedSM Generation 2

Continue to document any mutation testing results as needed.
4. **Histopathologic Type** is required to confirm patient has non-squamous NSCLC.



5. To view the treatment regimen ordered for the patient, click Flowsheet.
6. Review the listed treatment.

Clinical Profile

Problems Treatments Chart Alerts Care Plan **Medications** Allergies

▼ Cumulative Drug Dose **0** ADD OFFSITE DRUG DOSE **8**

Name	Offsite Dose	Dose Given	Total (Offsite Dose + Given)
<i>No Results Found</i>			

▼ Medication List **6** ADD EXTERNAL MED

VERIFY INACTIVATE ☒ Active ☐ Inactive ☐ Removed SHOW RX HX RECONCILE ELECTRONICALLY RECONCILE MANUALLY

Type/Description	Start Date
Prescriptions	
Erlotinib Oral 100 mg tablet 1 tablet orally every day. Take on an empty stomach, 1 hour before or 2 hours after food. Use of H2-blockers and PPI Pump Inhibitors should be avoided, if possible.	06/04/2018
Sulfadiazine Oral 500 mg tablet 1 tablet orally once. administer with large glass of water.	08/07/2018

External Medications

7. Oral treatment without a regimen will be listed under **Prescriptions**.
8. If the patient received an oral drug and a regimen was not entered, the drug will be listed on the **Medications** list under the **Clinical Profile** tab.

iKnowMedSM Generation 2

The screenshot displays the iKnowMed Generation 2 interface. On the left, a list of biomarkers is shown with expandable arrows: Metastatic Sites, Histopathologic Type, Histologic Grade, Tumor Size (cm), EGFR Expression (highlighted in yellow with the text 'Insufficient Tissue'), ALK, PD-L1, KRAS gene, ROS1 Gene, BRAF Mutation, and MET gene mutation. On the right, the 'EGFR Expression' section is active, showing radio button options: Positive-EGFR sensitizing mutation, T790M positive, Exon 20 insertion mutation positive, Negative, Equivocal, Not performed, and Unknown. Below these options is a text input field containing 'Insufficient Tissue', which is highlighted with a red box and a yellow circle labeled '9'. At the bottom right, there are three buttons: 'SAVE & ADD ANOTHER', 'SAVE & CLOSE' (highlighted with a red box and a yellow circle labeled '10'), and a 'CEL' button.

9. Patients will be excluded from the measure if there is not sufficient tissue for testing. To document use the text box for one the biomarkers and type Insufficient Tissue.

Note: *This only has to be entered for one biomarker not all five.*

10. Click **SAVE & CLOSE**.

This concludes the lesson for the **MIPS # PIMSH13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy** quality measure.